APA (7th ed.) Citation

Visentin, A., Imbergamo, S., Scomazzon, E., Pravato, S., Frezzato, F., Bonaldi, L., . . . Trentin, L. (2019). BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. Angewandte Chemie, 131(15), 193. https://doi.org/10.1111/bjh.15440

Chicago Style (17th ed.) Citation

Visentin, Andrea, et al. "BCR Kinase Inhibitors, Idelalisib and Ibrutinib, Are Active and Effective in Richter Syndrome." Angewandte Chemie 131, no. 15 (2019): 193. https://doi.org/10.1111/bjh.15440.

MLA (9th ed.) Citation

Visentin, Andrea, et al. "BCR Kinase Inhibitors, Idelalisib and Ibrutinib, Are Active and Effective in Richter Syndrome." Angewandte Chemie, vol. 131, no. 15, 2019, p. 193, https://doi.org/10.1111/bjh.15440.